Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer restated their outperform rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $9.00 price objective on the stock, down from their prior price objective of $10.00.

A number of other research firms also recently weighed in on VTYX. Canaccord Genuity Group lowered their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Tuesday, October 15th. Finally, Wells Fargo & Company cut their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Trading Down 1.8 %

Shares of VTYX opened at $2.20 on Friday. Ventyx Biosciences has a 12-month low of $1.79 and a 12-month high of $11.48. The company has a market cap of $155.47 million, a PE ratio of -0.93 and a beta of 0.37. The stock has a 50-day moving average price of $2.24 and a 200-day moving average price of $2.82.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). As a group, analysts predict that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Institutional Trading of Ventyx Biosciences

Institutional investors have recently made changes to their positions in the stock. Palumbo Wealth Management LLC bought a new stake in Ventyx Biosciences during the 3rd quarter valued at $26,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences during the second quarter valued at about $32,000. Intech Investment Management LLC purchased a new stake in shares of Ventyx Biosciences during the third quarter worth about $42,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.